drug

rondecabtagene autoleucel

1 story · latest Aug 6, 2026

Status: Investigational
Code: LYL314
Trials: 2 registered trials in coverage

Relationships

Developed by Lyell Immunopharma, Inc.

Timeline

Lyell reports Q2 2026 results, updated ronde-cel and LYL273 data

Aug 6Quarterly updateLyell Immunopharma, Inc.

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.